Analyst Ratings For Accelerate Diagnostics Inc (NASDAQ:AXDX)
Today, Piper Jaffray Companies raised its price target on Accelerate Diagnostics Inc (NASDAQ:AXDX) to $22.00 per share.
There are 2 Hold Ratings, 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Accelerate Diagnostics Inc (NASDAQ:AXDX) is Hold with a consensus target price of $21.00 per share, a potential 7.86% upside.
Some recent analyst ratings include
- 11/7/2018-Accelerate Diagnostics Inc (NASDAQ:AXDX) gets downgraded to Neutral by JPMorgan Chase & Co. with a price target of $16.00
- 5/24/2018-Accelerate Diagnostics Inc (NASDAQ:AXDX) has coverage initiated with a Hold rating and $25.00 price target
- 2/18/2018-Accelerate Diagnostics Inc (NASDAQ:AXDX) had its Hold rating reiterated by BTIG Research
- On 11/28/2018 Thomas D Brown, Director, bought 10,000 with an average share price of $13.65 per share and the total transaction amounting to $136,500.00.
- On 11/27/2018 Steven Reichling, Insider, bought 850 with an average share price of $13.13 per share and the total transaction amounting to $11,160.50.
- On 11/8/2018 John Patience, Director, bought 10,000 with an average share price of $14.96 per share and the total transaction amounting to $149,600.00.
- On 11/8/2018 Steven Reichling, Insider, bought 750 with an average share price of $14.72 per share and the total transaction amounting to $11,040.00.
- On 5/14/2018 Jack W Schuler, Director, bought 65,000 with an average share price of $19.97 per share and the total transaction amounting to $1,298,050.00.
- On 5/11/2018 Jack W Schuler, Director, bought 100,000 with an average share price of $19.33 per share and the total transaction amounting to $1,933,000.00.
- On 3/5/2018 Jack W Schuler, Director, bought 100 with an average share price of $25.00 per share and the total transaction amounting to $2,500.00.
About Accelerate Diagnostics Inc (NASDAQ:AXDX)
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Recent Trading Activity for Accelerate Diagnostics Inc (NASDAQ:AXDX)
Shares of Accelerate Diagnostics Inc closed the previous trading session at 19,47 −0,32 1,62 % with 409000 shares trading hands.